Collegium Pharmaceutical Stock Investor Sentiment
| COLL Stock | USD 29.66 1.32 4.26% |
About 68% of Collegium Pharmaceutical's investor base is looking to short. The analysis of overall sentiment of trading Collegium Pharmaceutical stock suggests that many investors are alarmed at this time. Collegium Pharmaceutical's investing sentiment shows overall attitude of investors towards Collegium Pharmaceutical.
Collegium |
Collegium Pharmaceutical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Collegium Pharmaceutical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Collegium Pharmaceutical that are available to investors today. That information is available publicly through Collegium media outlets and privately through word of mouth or via Collegium internal channels. However, regardless of the origin, that massive amount of Collegium data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Collegium Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Collegium Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Collegium Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Collegium Pharmaceutical alpha.
Collegium Pharmaceutical Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com | 12/04/2024 |
2 | High Court Judge Appears Before Top Court Collegium Over Majority Remarks Sources | 12/17/2024 |
3 | Disposition of 27500 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 21.34 subject to Rule 16b-3 | 01/10/2025 |
4 | Disposition of 6100 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 33.6427 subject to Rule 16b-3 | 01/14/2025 |
5 | Collegium Pharmaceutical Insiders Sell US2.3m Of Stock, Possibly Signalling Caution | 02/04/2025 |
6 | Collegium Pharmaceutical Price Target Lowered to 36.00 at Piper Sandler | 02/05/2025 |
7 | Disposition of 25149 shares by Shirley Kuhlmann of Collegium Pharmaceutical at 30.52 subject to Rule 16b-3 | 02/10/2025 |
8 | Rubric Capital Management LP Increases Stake in Collegium Pharmaceutical Inc | 02/14/2025 |
Check out Collegium Pharmaceutical Hype Analysis, Collegium Pharmaceutical Correlation and Collegium Pharmaceutical Performance. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share | Quarterly Revenue Growth 0.165 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.